Navigation Links
Watson Pharmaceuticals Announces New Research Showing RAPAFLO(R) (silodosin) Improves Outcomes for Chronic Prostatitis/Chronic Pelvic Pain Syndrome
Date:5/17/2011

or RAPAFLO(R) 4 mg, 13.3 percent for RAPAFLO(R) 8 mg, and 1.9 percent for placebo.

Study Design

The double-blind, 12-week, placebo-controlled Phase 2 study evaluated the safety and efficacy of RAPAFLO(R) in patients with moderate to severe non-bacterial CP/CPPS who previously had not received alpha-blockers for the condition.  Patients with National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) total score >/=15 (moderate to severe), NIH-CPSI pain score >/=8 (mild to moderate), and pelvic pain for >/=3 months before screening were randomized to RAPAFLO(R) 4 mg or 8 mg per day, or placebo. The primary measure of efficacy was improvement in the NIH-CPSI total score. Of 151 participants, 76.2 percent completed the study. The median age of patients was 48.2 years; 80.1 percent had experienced pain for at least one year.

Secondary end points evaluated were: safety; change from baseline in NIH-CPSI pain, urinary, and quality of life scores; and change from baseline in Medical Outcomes Study Short Form 12 (SF-12) physical and mental component scores. Additional secondary end points were percentages of participants who had a sufficiently significant decrease in total score (NIH-CPSI responders) and of those who indicated "markedly improved" or "moderately improved" on the global response assessment (GRA) scale (GRA responders).

About RAPAFLO(R) (silodosin)

RAPAFLO(R) was first approved by the FDA two years ago for the treatment of signs and symptoms of benign prostatic hyperplasia (BPH). RAPAFLO(R) is an effective, uniquely selective alpha-1 adrenergic receptor antagonist. RAPAFLO(R) maximizes target organ activity by binding with high affinity to the alpha (1A) receptors concentrated in the prostate. The antagonism of these receptors cause the smooth muscles in these tissues to relax and results in improved urine flow and a reduction in BPH symptoms. The binding affinity for the alp
'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Watson Confirms Renvela® Patent Challenge
2. Delaware Court Rules That Watson Does Not Infringe Patent Related to Generic Version of Concerta(R) and Declares Patent Invalid
3. Watsons GELNIQUE(TM) (oxybutynin chloride) Gel 10% Approved by FDA for the Treatment of Overactive Bladder
4. Auxilium Pharmaceuticals, Inc. Announces First Quarter 2011 Financial Results and Operational Highlights
5. Inovio Pharmaceuticals Reports Long-Term Immune Responses from Therapeutic Cervical Dysplasia and Cancer DNA Vaccine
6. Vanda Pharmaceuticals Reports First Quarter 2011 Results
7. MAP Pharmaceuticals Reports First Quarter of 2011 Financial Results
8. Anadys Pharmaceuticals to Report First Quarter 2011 Financial Results
9. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2011 Financial Results
10. Keryx Biopharmaceuticals, Inc. To Host Conference Call on First Quarter 2011 Financial Results
11. Keryx Biopharmaceuticals Announces Positive Final Data from Zerenex™ Short-Term Phase 3 Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... 28, 2015  PDL BioPharma, Inc. (PDL, or the ... Company will release its second quarter 2015 financial results ... August 5, 2015, after market close. PDL,s management will ... 4:30 p.m. Eastern Time to discuss the financial results. ... available via the webcast link on the PDL website. ...
(Date:7/28/2015)... , ... July 28, 2015 , ... ... than EUR 1.022 billion in 2013; while production volume reached close to 1.84 ... producing country with a share of 75.5% of the region’s total aluminium hydroxide ...
(Date:7/28/2015)... ... July 28, 2015 , ... VetStem Biopharma will be offering weekly private guided ... local area veterinarians. , The tour and course will be given every Wednesday at ... VetStem’s Poway facility. Staff members are welcome to attend with their veterinarian as well. ...
(Date:7/28/2015)... July 28, 2015  Kerastem Technologies announce that the ... U.S. FDA Center For Biologics Evaluation and Research (CBER) ... a clinical trial investigating the safety and feasibility of ... early male pattern baldness (androgenic alopecia). The ... initial clinical work in Europe ...
Breaking Biology Technology:PDL BioPharma to Announce Second Quarter 2015 Financial Results on August 5, 2015 2EU27 Aluminium Hydroxide Market Analysed and Forecast by BAC Reports in New Research Study Available at MarketPublishers.com 2EU27 Aluminium Hydroxide Market Analysed and Forecast by BAC Reports in New Research Study Available at MarketPublishers.com 3VetStem Biopharma weekly veterinary continuing education classes and GMP manufacturing facility tour 2Kerastem Receives Conditional Approval from FDA for Alopecia Trial 2
... Technology Council , a policy advisor to the governor ... eight additions to its board of directors. , ,The ... board that includes more than three dozen members of ... organization leaders: , , Eric Apfelbach, president and CEO ...
... Sciences today announced the release of a product that ... proteins, and perhaps improve the cost effectiveness of drug discovery. ... an extension of the company's existing PreserveX line, and it ... Society of Japan in Kyoto, Japan. CEO Ralph Kauten said ...
... move forward on its deployment of Project Lightspeed? , ,If ... be setting its sights higher on real broadband and long-term ... marketing strategy of Project Lightspeed should be to get fiber ... a true broadband package. Instead, it is a way to ...
Cached Biology Technology:AT&T should set sights higher than repackaging DSL with Project Lightspeed 2AT&T should set sights higher than repackaging DSL with Project Lightspeed 3AT&T should set sights higher than repackaging DSL with Project Lightspeed 4AT&T should set sights higher than repackaging DSL with Project Lightspeed 5AT&T should set sights higher than repackaging DSL with Project Lightspeed 6
(Date:7/23/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/rzzp3v/global_outlook_of ) has ... of the Biometrics Industry 2015 " report ... biometrics market is likely to witness significant growth ... the uptake of multiple technologies available. The year ... growth of biometrics in existing applications as well ...
(Date:7/21/2015)... 2015 Passwords have proven futile for ... recent U.S. Office of Personnel Management breach. Biometric ... conundrum, but developers and end-users are concerned about ... dilemma, Biometrics-as-a-Service provider HYPR Corp. announced today the ... third party integration. A video ...
(Date:7/13/2015)... , Jul. 13, 2015 NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile ... provisional patent 62/188684 for BEHAVIORAL-DIRECTED AUTHENTIATION ... new convenient and secure method to make payments.  ... payment methods, introduced with its groundbreaking voice-direct payment ...
Breaking Biology News(10 mins):Global Outlook of the Biometrics Industry 2015 2Global Outlook of the Biometrics Industry 2015 3HYPR Corp. Launches Industry First Biometric Tokenization Platform 2HYPR Corp. Launches Industry First Biometric Tokenization Platform 3HYPR Corp. Launches Industry First Biometric Tokenization Platform 4NXT-ID Patents Behavior-Directed Payments 2NXT-ID Patents Behavior-Directed Payments 3NXT-ID Patents Behavior-Directed Payments 4
... just been seen by synchronizing brain waves in a working ... of Health suggests. The more in-sync such electrical signals of ... more those cells held the short-term memory of a just-seen ... a grantee of NIH,s National Institute of Mental Health (NIMH), ...
... USA In the evolutionary long run, small critters tend ... the idea attributed to paleontologist Edward Cope, now known as ... new test of this rule as it applies dinosaurs shows ... long time, dinosaurs were thought to be the example of ...
... in Norway have found new support for their theory ... non-psychotic individuals, leading to long-term psychosis. In an fMRI ... , researchers found a different brain activity pattern in ... patients without prior cannabis use. The results ...
Cached Biology News:In-sync brain waves hold memory of objects just seen 2Were dinosaurs destined to be big? Testing Cope's rule 2Cannabis use mimics cognitive weakness that can lead to schizophrenia 2
... Young rabbit blood (New Zealand White ... either sex) is refrigerated within 6 hours ... frozen at -20ºC. The serum is then ... a standard in-house protocol, filtered through a ...
... imaging system from Molecular Devices ... system for automated acquisition and analysis ... screening. ImageXpressULTRA is powered by ... screening acquisition, image storage and analysis. ...
... Host Strain Competent Cell Sets Sets ... strain combinations The most common ... E. coli is to use chemically ... prepared in the laboratory, greater efficiency, reproducibility ...
... The BD Pathway Bioimager is an automated, ... imaging system that has been integrated into ... Pathway was designed to provide high-resolution, automated ... assist in developing better cell-based assays. The ...
Biology Products: